LULL(ed) into complacency: A perspective on licenses and stem cell translational science

Stem Cell Research and Therapy

Volumn 4, Issue 4, 2013, Pages

  Rao, Mahendra S ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOENGINEERING; BIOTECHNOLOGICAL PRODUCTION; EMBRYONIC STEM CELL; FUNDING; GOVERNMENT REGULATION; INFORMED CONSENT; LICENSING; MESENCHYMAL STEM CELL; PATENT; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROCESS CONTROL; PRODUCT DEVELOPMENT; PUBLIC-PRIVATE PARTNERSHIP; REGENERATIVE MEDICINE; REVIEW; STEM CELL RESEARCH; UNITED STATES; HUMAN; LEGISLATION AND JURISPRUDENCE; STANDARDS; TRANSLATIONAL RESEARCH; TRENDS;

HUMANS; LICENSURE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84887917292     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt309     Document Type: Review

References (17)

1. The stakes in Bayh-Dole: public values beyond the pace of innovation. Valdivia WD, Minerva 2011 49 25 46 10.1007/s11024-011-9162-6 21475661
2. The gold rush for induced pluripotent stem cells. Webb S, Nat Biotechnol 2009 27 977 979 10.1038/nbt1109-977 19898444
3. Power-laws and the use of pluripotent stem cell lines. Schuldt BM, Guhr A, Lenz M, Kobold S, Macarthur BD, Schuppert A, Loser P, Muller FJ, PLoS One 2013 8 52068 10.1371/journal.pone.0052068 23300961
4. Stem cell research policy and iPS cells. Caulfield T, Scott C, Hyun I, Lovell-Badge R, Kato K, Zarzeczny A, Nat Methods 2010 7 28 33 10.1038/nmeth.f.282 20038953
5. Pluripotent human stem cells: a novel tool in drug discovery. Phillips BW, Crook JM, BioDrugs 2010 24 99 108 10.2165/11532270-000000000-00000 20199125
6. Human induced pluripotent stem cells: a review of the US patent landscape. Georgieva BP, Love JM, Regen Med 2010 5 581 591 10.2217/rme.10.43 20632861
7. Empirical analysis of major stem cell patent cases: the role of universities. Mills AE, Tereskerz PM, Nat Biotechnol 2010 28 325 328 10.1038/nbt0410-325 20379173
8. iPS cells: mapping the policy issues. Zarzeczny A, Scott C, Hyun I, Bennett J, Chandler J, Chargé S, Heine H, Isasi R, Kato K, Lovell-Badge R, McNagny K, Pei D, Rossant J, Surani A, Taylor PL, Ogbogu U, Caulfield T, Cell 2009 139 1032 1037 10.1016/j.cell.2009.11.039 20005794
9. Specimen collection for induced pluripotent stem cell research: harmonizing the approach to informed consent. Lowenthal J, Lipnick S, Rao M, Hull SC, Stem Cells Transl Med 2012 1 409 421 10.5966/sctm.2012-0029 23197820
10. Assessing iPSC reprogramming methods for their suitability in translational medicine. Rao MS, Malik N, J Cell Biochem 2012 113 3061 3068 10.1002/jcb.24183 22573568
11. Balancing open source stem cell science with commercialization. Courtney A, de Sousa P, George C, Laurie G, Tait J, Nat Biotechnol 2011 29 115 116 10.1038/nbt.1773 21301432
12. Residual expression of the reprogramming factors prevents differentiation of iPSC generated from human fibroblasts and cord blood CD34+ progenitors. Ramos-Mejia V, Montes R, Bueno C, Ayllon V, Real PJ, Rodriguez R, Menendez P, PLoS One 2012 7 35824 10.1371/journal.pone.0035824 22545141
13. From banking to international governance: fostering innovation in stem cell research. Isasi R, Knoppers BM, Stem Cells Int 2011 2011 498132 21904557
14. Patents on technologies of human tissue and organ regeneration from pluripotent human embryonic stem cells. Parsons XH, Teng YD, Moore DA, Snyder EY, Rec Pat Regen Med 2011 1 142 163 23355961
15. Advances in targeted genome editing. Perez-Pinera P, Ousterout DG, Gersbach CA, Curr Opin Chem Biol 2012 16 268 277 10.1016/j.cbpa.2012.06.007 22819644
16. RNA-guided human genome engineering via Cas9. Mali P, Yang L, Esvelt KM, Aach J, Guell M, Dicarlo JE, Norville JE, Church GM, Science 2013 339 823 826 10.1126/science.1232033 23287722
17. Multiplex genome engineering using CRISPR/Cas systems. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F, Science 2013 339 819 823 10.1126/science.1231143 23287718